- Report
- May 2024
- 139 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- October 2024
- 197 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- March 2025
- 194 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- April 2023
- 120 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- October 2023
- 74 Pages
Global
From €3500EUR$3,944USD£3,043GBP
Proliferative Vitreoretinopathy (PVR) is a sight-threatening disorder of the retina that occurs when abnormal tissue growth occurs in the vitreous cavity of the eye. It is a common complication of retinal detachment surgery and can lead to further vision loss. PVR is a major cause of blindness in the developed world and is a growing problem in the developing world.
The optical market for PVR is focused on the development of treatments and technologies to diagnose and treat the disorder. These include diagnostic imaging techniques such as optical coherence tomography (OCT) and fluorescein angiography, as well as treatments such as vitrectomy, laser photocoagulation, and intravitreal injections.
Companies in the PVR market include Alcon, Bausch + Lomb, Carl Zeiss Meditec, Heidelberg Engineering, and Topcon. Show Less Read more